Maze Therapeutics to Participate in Upcoming Investor Conferences
Maze to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Maze Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829
Statement on FTC challenge to proposed license agreement with Maze Therapeutics
Maze Therapeutics Highlights New Preclinical Data Supporting Advancement of APOL1 Inhibitor Candidate Toward Clinical Evaluation for APOL1 Kidney Disease
Maze Therapeutics to Present New Data for APOL1 Kidney Disease in Proprietary Chronic Preclinical Model Demonstrating Reversal of Albuminuria
Maze Therapeutics Announces Publication of Research Demonstrating Newly Identified Variant for APOL1 Kidney Disease is Associated with Reduced Risk of APOL1 Kidney Disease
Maze Therapeutics to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will present a company overview at the 2023 Jefferies Healthcare Conference on Thursday, June 8, 2023, at 11:30 a.m. ET.
Sanofi is offering up to $750 million in upfront cash and biobucks for Maze Therapeutics’ glycogen synthase 1 (GYS1) program, including a lead asset that’s recently completed a phase 1 trial for patients with Pompe disease.